Craig-Hallum Maintains Buy on Acasti Pharma, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Acasti Pharma (NASDAQ:ACST) and raises the price target from $6 to $8.
September 26, 2024 | 4:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Craig-Hallum has reaffirmed its Buy rating on Acasti Pharma and increased the price target from $6 to $8, indicating a positive outlook on the stock.
The increase in price target from $6 to $8 by Craig-Hallum suggests a positive sentiment and potential upside for Acasti Pharma's stock. This is likely to attract investor interest and could lead to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100